Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Keywords:gender, sex, gender bias, sex bias, psoriasis, biological therapy, drug prescription, drug safety
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
Jahn I, Bornhorst C, Gunther F, Brand T. Examples of sex/gender sensitivity in epidemiological research: results of an evaluation of original articles published in JECH 2006-2014. Health Res Policy Syst 2017; 15: 11.
Mazure CM, Jones DP. Twenty years and still counting: including women as participants and studying sex and gender in biomedical research. BMC Womens Health 2015; 15: 94.
Takeshita J. Identifying Disparities in dermatology: the importance of measuring differences that matter. JAMA Dermatol 2018; 154: 1251-1253.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205-212.
Hagg D, Eriksson M, Sundstrom A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One 2013; 8: e63619.
van der Schoot LS, van den Reek J, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol 2019; 33: 1913-1920.
Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol 2017; 18: 583-590.
Regitz-Zagrosek V. Sex and gender differences in health. Science & Society Series on Sex and Science. EMBO Rep 2012; 13: 596-603.
Bohm D, Stock Gissendanner S, Bangemann K, Snitjer I, Werfel T, Weyergraf A, et al. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol 2013; 27: 220-226.
Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res 2016; 25: 2739-2754.
Wojtyna E, ?akuta P, Marcinkiewicz K, Bergler-Czop B, Brzezi?ska-Wcis?o L. Gender, Body image and social support: biopsychosocial deter-minants of depression among patients with psoriasis. Acta Derm Venereol 2017; 97: 91-97.
Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol 2016; 175: 340-347.
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential Drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632-2640.
Davila-Seijo P, Garcia-Doval I. Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis. Actas Dermosifiliogr 2017; 108: 3-5.
Rivera R, Garcia-Doval I, Carretero G, Dauden E, Sanchez-Carazo J, Ferrandiz C, et al. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]. Actas Dermosifiliogr 2011; 102: 132-141 (in Spanish).
Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol 2017; 137: 313-321.
D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011; 30: 377-399.
Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991; 10: 585-598.
Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 2017; 36: 4391-4400.
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251-265.e219.
Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 2012; 10: 82.
Fernandez-Torres RM, Pita-Fernandez S, Fonseca E. Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruna, Spain. Int J Dermatol 2014; 53: e507-511.
Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 2019; 33: 700-708.
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol 2019; 180: 1069-1076.
Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol 2013; 177: 292-298.
Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, et al. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges 2017; 15: 309-317.
Pogácsás L, Borsi A, Takács P, Remenyik É, Kemény L, Kárpáti S, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatol Treat 2017; 28: 635-641.
Runnels V, Tudiver S, Doull M, Boscoe M. The challenges of including sex/gender analysis in systematic reviews: a qualitative survey. Syst Rev 2014; 3: 33.
Di Cesare A, Bianchi C, Pescitelli L, Ricceri F, Rosi E, Pimpinelli N, et al. Risk of acute infections in psoriatic patients during biologic therapies is linked to gender. J Eur Acad Dermatol Venereol 2019; 33: e362-e364.
Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2019; 181: 450-458.
How to Cite
Copyright (c) 2021 Carlos Pelayo Hernández-Fernández, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Esteban Daudén, Pablo de la Cueva, Isabel Belinchón, Francisco Javier Gómez-García, Enrique Herrera-Acosta, Diana P. Ruiz-Genao, Marta Ferrán, Mercé Alsina, Ofelia Baniandrés-Rodríguez, José Luis Sánchez-Carazo, Rafael Botella-Estrada, Antonio Sahuquillo-Torralba, Lourdes Rodríguez, Jaime Vilar-Alejo, Carmen García-Donoso, José M. Carrascosa, Mar Llamas-Velasco, Enrique Herrera-Ceballos, Jose Luis López-Estebaranz, Conrad Pujol-Marco, Miguel Angel Descalzo, Ignacio Garcia-Doval
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.